Volpara Health Technologies Ltd. engages in selling the VolparaEnterprise software, which is a cloud-based breast imaging analytics product. The firm provides its goods and services under three product categories: software as a service (SaaS) contract, software maintenance agreements (SMAs) and capital sales contracts. Software as a service (SaaS) contract involves the sale of software on a subscription basis and, where applicable, cloud-based support. SaaS contracts comprise a range of goods and services, including the base software, software updates and upgrades, installation, integrations, and other. Software maintenance agreements (SMAs) support previous capital sales. SMA contracts comprise a number of distinct performance obligations, including the provision of software updates, upgrades, provision of ongoing technical support, and other. Capital sales contracts involve the outright sale of software and associated items.
Volpara Health Technologies (ASX: VHT)
- Home
- Volpara Health Technologies (ASX: VHT)
Here are the latest articles on Volpara Health Technologies (ASX: VHT)
Volpara cash flow positive for fourth consecutive quarter as demand for early breast cancer detection tech grows
October 17, 2023
HealthTech company focused on early detection of breast cancer, Volpara Health (ASX: VHT), has reported a fourth consecutive positive net operating cash flow quarter. As a result, it does not have to submit quarterly ASX updates anymore. What’s better, the Company surpassed its initial guidance by a year and a half. For the quarter ended
Volpara teams up with BreastScreen Victoria to implement AI imaging for breast cancer
June 7, 2023
As medical technology continues to advance, digital imaging is now a staple for image interpretation for cancer diagnosis, especially in finding potential abnormalities that aren’t visible to the eyes as well as evaluating the extent of the disease. Breast cancer software company Volpara (ASX: VHT) is among those that offers what it takes to meet
Volpara signs on five new large healthcare companies for breast cancer risk assessment tech
January 9, 2023
Artificial intelligence biotech company Volpara Health (ASX: VHT) has started the year by raking in the money (is there a better way?), and shareholders are here for it. Volpara has signed five contracts worth $11.34 million (NZ$12.3 million) combined. The five-year contracts include some leading US healthcare companies, including Bon Secours Mercy Health, Northside Hospital,
Volpara simplifying breast cancer communication for women with AI-driven imagery
October 26, 2020
At a time when women are more aware of potential health issues than ever, Volpara Health (ASX: VHT) is set to drastically improve how breast cancer is talked about with imaging technology driven by artificial intelligence that will help prevent advanced stage breast cancer. The imagery will be provided to women in collaboration with Sheila
Recent Articles
